ᱨᱮᱫ:PegUricase.png
ᱧᱮᱞᱡᱚᱝ ᱨᱮᱱᱟᱜ ᱟᱠᱟᱨ:᱖᱑᱕ × ᱕᱙᱙ ᱯᱤᱠᱥᱮᱞ ᱮᱴᱟᱜ ᱨᱤᱡᱚᱞᱩᱥᱚᱱᱥ: ᱒᱔᱖ × ᱒᱔᱐ ᱯᱤᱠᱥᱮᱞ | ᱔᱙᱓ × ᱔᱘᱐ ᱯᱤᱠᱥᱮᱞ | ᱗᱘᱘ × ᱗᱖᱘ ᱯᱤᱠᱥᱮᱞ | ᱑,᱐᱕᱑ × ᱑,᱐᱒᱔ ᱯᱤᱠᱥᱮᱞ | ᱒,᱑᱙᱒ × ᱒,᱑᱓᱖ ᱯᱤᱠᱥᱮᱞ
ᱟᱥᱚᱞ ᱨᱮᱫ (᱒,᱑᱙᱒ x ᱒,᱑᱓᱖ pixels, file size: ᱑.᱖᱕ MB, MIME type: image/png)
ᱢᱩᱬᱩᱛ ᱠᱟᱛᱷᱟ
| ᱵᱤᱵᱚᱨᱚᱱᱤ |
English: A comparison of uricase (pdb:1uox) and PEG-uricase (model). PEG-uricase includes 40 polymers of 10kDa PEG. PEGylation improves its solubility at physiological pH, increases serum half-life and reduces immunogenicity without compromising activity. Upper images show the whole tetramer, lower images show an example of one of the lysines that is PEGylated. (PEG-uricase model from reference[1], only 36 PEG polymers included) |
| ᱢᱟᱹᱦᱤᱛ | |
| ᱯᱷᱮᱰᱟᱛ | ᱤᱧᱟᱜ ᱠᱟᱹᱢᱤ |
| ᱚᱱᱚᱞᱤᱭᱟᱹ | Evolution and evolvability |
ᱞᱟᱭᱥᱮᱱᱥ ᱛᱮᱭᱟᱨ
I, the copyright holder of this work, hereby publish it under the following license:
This file is licensed under the Creative Commons Attribution 4.0 International license.
- ᱟᱲᱟᱜ ᱜᱮᱭᱟᱢ:
- ᱦᱟᱹᱴᱤᱧᱢᱮ – ᱱᱚᱠᱚᱞ ᱞᱟᱹᱜᱤᱫ, ᱦᱟᱹᱴᱤᱧ ᱟᱨ ᱵᱷᱮᱡᱟᱭᱢᱮ ᱠᱟᱹᱢᱤ
- ᱢᱮᱥᱟᱣᱠᱟᱛᱢᱮ – ᱠᱟᱹᱢᱤ ᱟᱞᱜᱟᱭ ᱞᱟᱹᱜᱤᱫ
- ᱞᱟᱛᱟᱨ ᱨᱮᱭᱟᱜ ᱨᱤᱛ ᱞᱮᱠᱟᱛᱮ:
- ᱟᱴᱨᱤᱵᱩᱥᱚᱱ – ᱟᱢ ᱠᱟᱹᱢᱤ ᱥᱚᱫᱚᱨ ᱦᱩᱭᱟᱢᱟ ᱡᱚᱠᱷᱚᱱ ᱚᱱᱚᱞᱤᱭᱟᱹ ᱟᱨᱵᱟᱝ ᱞᱟᱭᱥᱮᱸᱥᱩᱭᱟᱹ ᱫᱟᱨᱟᱭᱛᱮ ᱠᱟᱛᱷᱟ ᱨᱟᱠᱟᱵ ᱠᱷᱟᱱ (ᱢᱮᱱᱠᱷᱟᱱ ᱟᱠᱚ ᱩᱫᱩᱜᱟᱜ ᱦᱚᱨ ᱛᱮᱫᱚ ᱵᱟᱝ ᱡᱟᱦᱟᱸ ᱟᱠᱚᱠᱚ ᱜᱚᱲᱚᱣᱟᱢ ᱟᱨᱵᱟᱝ ᱟᱢᱟᱜ ᱠᱟᱹᱢᱤ ᱨᱮᱱᱟᱜ ᱵᱮᱵᱷᱟᱨ)
- ↑ (3 January 2008). "PEG-uricase in the management of treatment-resistant gout and hyperuricemia.". Advanced drug delivery reviews 60 (1): 59-68. PMID 17826865.
ᱨᱮᱫ ᱨᱮᱭᱟᱜ ᱱᱟᱜᱟᱢ
ᱚᱠᱛᱚ ᱨᱮ ᱞᱤᱱ ᱢᱮ/ᱚᱠᱛᱚ ᱨᱮ ᱨᱮᱫ ᱧᱮᱞ ᱞᱟᱹᱜᱤᱛ ᱞᱤᱱ ᱢᱮ
| ᱢᱟᱹᱦᱤᱛ/ᱚᱠᱛᱚ | ᱴᱤᱯ | ᱡᱚᱠᱷᱟ | ᱵᱮᱵᱷᱟᱨᱤᱭᱟᱹ | ᱠᱟᱛᱷᱟ | |
|---|---|---|---|---|---|
| ᱱᱤᱛᱚᱜ | ᱒᱓:᱕᱐, ᱒᱑ ᱯᱷᱮᱵᱽᱨᱩᱣᱟᱨᱤ ᱒᱐᱑᱕ | | ᱒,᱑᱙᱒ × ᱒,᱑᱓᱖ (᱑.᱖᱕ MB) | Evolution and evolvability | User created page with UploadWizard |
ᱯᱷᱟᱭᱤᱞ ᱵᱮᱣᱦᱟᱨ
ᱱᱚᱸᱰᱮ ᱫᱚ ᱟᱨ ᱮᱴᱟᱜ ᱥᱟᱦᱴᱟᱠᱚ ᱵᱟᱱᱩᱜ-ᱟ ᱡᱟᱸᱦᱟᱸ ᱥᱟᱶᱛᱮ ᱱᱤᱭᱟᱹ ᱨᱮᱫ ᱨᱮᱱᱟᱜ ᱡᱚᱱᱚᱲ ᱢᱮᱱᱟᱜ-ᱟ
ᱡᱮᱜᱮᱛ ᱡᱟᱠᱟᱛ ᱨᱮᱫ ᱵᱮᱵᱷᱟᱨᱟᱜ
ᱱᱚᱶᱟ ᱨᱮᱫᱠᱚ ᱵᱮᱵᱷᱟᱨᱟᱠᱟᱫ ᱣᱤᱠᱤᱠᱚ :
- cs.wikipedia.org ᱨᱮ ᱵᱮᱣᱦᱟᱨ
- de.wikipedia.org ᱨᱮ ᱵᱮᱣᱦᱟᱨ
- en.wikipedia.org ᱨᱮ ᱵᱮᱣᱦᱟᱨ
- gl.wikipedia.org ᱨᱮ ᱵᱮᱣᱦᱟᱨ
- ms.wikipedia.org ᱨᱮ ᱵᱮᱣᱦᱟᱨ
